Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-03-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/3/e011845.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032326527942656 |
|---|---|
| author | Xudong Zhu |
| author_facet | Xudong Zhu |
| author_sort | Xudong Zhu |
| collection | DOAJ |
| format | Article |
| id | doaj-art-d285e419fdca4c09ae7b999d943c8dd1 |
| institution | DOAJ |
| issn | 2051-1426 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-d285e419fdca4c09ae7b999d943c8dd12025-08-20T02:58:40ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262025-03-0113310.1136/jitc-2025-011845Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’Xudong Zhu0Department of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning Province, People`s Republic of Chinahttps://jitc.bmj.com/content/13/3/e011845.full |
| spellingShingle | Xudong Zhu Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ Journal for ImmunoTherapy of Cancer |
| title | Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ |
| title_full | Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ |
| title_fullStr | Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ |
| title_full_unstemmed | Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ |
| title_short | Comment on ‘Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study’ |
| title_sort | comment on pembrolizumab hybrid dosing is non inferior to flat dosing in advanced non small cell lung cancer a real world retrospective bicenter cohort study |
| url | https://jitc.bmj.com/content/13/3/e011845.full |
| work_keys_str_mv | AT xudongzhu commentonpembrolizumabhybriddosingisnoninferiortoflatdosinginadvancednonsmallcelllungcancerarealworldretrospectivebicentercohortstudy |